{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ranitidine+150+mg", "query": { "intervention": "ranitidine 150 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T01:37:18.922Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05338502", "title": "Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Ranitidine", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2019-07-08", "completion_date": "2019-09-03", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05338502" }, { "nct_id": "NCT01908257", "title": "Lesinurad Interaction Study With Ranitidine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "lesinurad 400 mg", "type": "DRUG" }, { "name": "ranitidine 150 mg", "type": "DRUG" }, { "name": "lesinurad 400 mg + ranitidine 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 16, "start_date": "2013-07", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2014-01-09", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01908257" }, { "nct_id": "NCT00838526", "title": "Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal Reflux Disease (GERD)" ], "interventions": [ { "name": "Rabeprazole ER", "type": "DRUG" }, { "name": "Ranitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 240, "start_date": "2008-08-31", "completion_date": "2009-12-31", "has_results": true, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 4, "location_summary": "Moline, Illinois", "locations": [ { "city": "Moline", "state": "Illinois" }, { "city": "Moline", "state": "Illinois" }, { "city": "Moline", "state": "Illinois" }, { "city": "Moline", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00838526" }, { "nct_id": "NCT01539655", "title": "Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medullary Thyroid Cancer" ], "interventions": [ { "name": "vandetanib", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" }, { "name": "ranitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 34, "start_date": "2012-02", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01539655" }, { "nct_id": "NCT00223691", "title": "Treatment of Orthostatic Hypotension in Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autonomic Failure", "Orthostatic Hypotension" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Acarbose", "type": "DRUG" }, { "name": "Pyridostigmine Bromide", "type": "DRUG" }, { "name": "Yohimbine", "type": "DRUG" }, { "name": "Midodrine HCl", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Modafinil", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "water intake", "type": "OTHER" }, { "name": "Diphenhydramine Hydrochloride", "type": "DRUG" }, { "name": "Ranitidine HCL", "type": "DRUG" }, { "name": "Tranylcypromine", "type": "DRUG" }, { "name": "Ergotamine/ Caffeine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Pseudoephedrine", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Oxymetazoline 0.05% nasal solution", "type": "DRUG" }, { "name": "Bovril", "type": "DIETARY_SUPPLEMENT" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "Rivastigmine tartrate", "type": "DRUG" }, { "name": "Carbidopa/levodopa", "type": "DRUG" }, { "name": "Inflatable abdominal binder", "type": "DEVICE" }, { "name": "inflatable abdominal binder (sham)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 389, "start_date": "2002-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223691" }, { "nct_id": "NCT01042704", "title": "Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Prophylaxis", "type": "DRUG" }, { "name": "Antibiotic", "type": "DRUG" }, { "name": "Biweekly Follow Up", "type": "OTHER" }, { "name": "Cyclical Follow Up", "type": "OTHER" }, { "name": "Restaging", "type": "OTHER" }, { "name": "Post-Treatment Follow Up", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Robert Redner, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2008-02", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2017-07-31", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 22, "location_summary": "Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Steubenville", "state": "Ohio" }, { "city": "Beaver", "state": "Pennsylvania" }, { "city": "Clairton", "state": "Pennsylvania" }, { "city": "Greensburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042704" }, { "nct_id": "NCT00839306", "title": "Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal Reflux Disease (GERD)" ], "interventions": [ { "name": "Rabeprazole ER", "type": "DRUG" }, { "name": "Ranitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 240, "start_date": "2008-08", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 4, "location_summary": "Moline, Illinois", "locations": [ { "city": "Moline", "state": "Illinois" }, { "city": "Moline", "state": "Illinois" }, { "city": "Moline", "state": "Illinois" }, { "city": "Moline", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00839306" }, { "nct_id": "NCT01682408", "title": "Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)", "type": "DRUG" }, { "name": "Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed", "type": "DRUG" }, { "name": "Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)", "type": "DRUG" }, { "name": "Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)", "type": "DRUG" }, { "name": "Ranitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2012-09", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-28", "last_synced_at": "2026-09-09T01:37:18.922Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682408" } ] }